<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To study the methylation status of fragile histidine triad (FHIT) gene promoter in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and its clinical relevance </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Methylation-specific PCR (MSP) was used to detect FHIT promoter methylation in bone marrow samples from 54 MDS cases </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Hypermethylation of FHIT promoter was detected in 26 cases (48.1%) </plain></SENT>
<SENT sid="3" pm="."><plain>Association was not found between FHIT gene hypermethylation and sex, hematologic parameters and chromosomal abnormalities of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, but found between FHIT gene hypermethylation and age of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases </plain></SENT>
<SENT sid="4" pm="."><plain>Although significant difference was not observed in the frequencies of FHIT gene hypermethylation among patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>/<z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (RA/<z:mp ids='MP_0011356'>RAS</z:mp>) (1/6, 16.7%), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>/<z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>) and refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> with ringed blasts (<z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e>) (6/19, 31.6%), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts-1 (<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e>) (7/11, 63.6%), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts-2 (<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e>) (4/7, 57.1%) and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (RAEBt/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (8/11, 72.7%)(chi-square=8.417, P=0.077), it was observed in patients in early stages (RA/<z:mp ids='MP_0011356'>RAS</z:mp> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>) (7/25, 28.0%), advanced stages (<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e> and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e>)(11/18, 61.1%) and RAEBt/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (8/11, 72.7%) (chi-square=7.938, P=0.019) </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, there was a positive correlation between the frequency of FHIT gene hypermethylation and different IPSS groups (chi-square=10.110, P=0.018) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: FHIT gene hypermethylation might be one of the molecular events involved in the disease progression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>